1. Home
  2. |Insights
  3. |International Trade in 2021: What’s Ahead

International Trade in 2021: What’s Ahead

Webinar | 02.17.21, 6:00 AM EST - 7:30 AM EST

Register

The incoming Biden administration faces a number of serious international trade issues, including increased tensions with China, the implementation of Brexit, and last, but far from least, a global pandemic that continues to impact global supply chains, mobility, and many other aspects of our interconnected world. Join us as we identify these issues along with many other international trade opportunities and risks likely to arise for your businesses in the course of 2021.


On Wednesday, February 17, 2021 from 11:00 am – 12:30 pm Eastern, our Crowell & Moring team will discuss predictions for the coming year. Topics will include likely trends and issues in the U.S., EU, and Asia including: 

  • Global Mobility
  • Supply Chain Risk Management
  • Trade Policy
  • EU Trade and Brexit
  • Customs
  • Trade Remedies
  • Section 337 Unfair Import Investigations
  • CFIUS and Team Telecom
  • Sanctions and Export Controls
  • Anti-Money Laundering (AML)

Presenters will include members of our International Trade Practice and Crowell & Moring International based in Washington, D.C., Los Angeles, Brussels, London, and Singapore. We hope you can join us for this webinar.

For more information, please visit these areas: International Trade

Insights

Webinar | 12.10.26

The Third-Party Perspective: Protecting Payors’ Interests in Antitrust Investigations

The Trump administration has sharpened its focus on hospital systems as a key driver of rising health care costs, and the DOJ and FTC are actively patrolling for anticompetitive conduct and mergers that contribute to these rising costs. Managed care organizations are a critical source of evidence in these investigations and are likely to receive Civil Investigative Demands (CIDs), be contacted by agency staff, or may consider proactively engaging with antitrust authorities to address competitive concerns in their markets.

View All Insights